Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Arcellx Inc ACLX

Healthcare Biotechnology
Arcellx, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of controllable cell therapies for the treatment of patients with cancer and other incurable diseases. The Company’s lead program is a BCMA-targeting ddCAR product candidate called CART-ddBCMA, which is being evaluated in its pivotal Phase II iMMagine-1 trial in patients with relapsed or... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ACLX)

Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights

Business Wire November 7, 2024

Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study

Business Wire November 5, 2024

Arcellx Provides Second Quarter 2024 Financial Results and Business Updates

Business Wire August 8, 2024

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

Business Wire May 9, 2024

Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

Business Wire May 9, 2024

Arcellx Provides First Quarter 2024 Financial Results

Business Wire May 9, 2024

Arcellx to Participate in Two Upcoming Investor Conferences

Business Wire May 7, 2024

Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Business Wire April 4, 2024

Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Business Wire March 20, 2024
View More News ››

Opinion & Analysis (NDAQ:ACLX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ACLX)

Be the first to post on this bullboard.

Viva Gold Corp.

Viva Gold Corp.

Viva Gold Corp. is a Canada-based gold exploration and development company, The Company’s business is the acquisition ...
View More »